Latest News-Ascentage Pharma Mediaroom_Page

Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety

SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2024-06-04 12:51 1509

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2024-05-24 09:15 1822

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2024-05-16 09:03 1708

ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST

SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2024-04-25 09:02 1586

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2024-04-08 07:58 1482

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2024-03-27 22:30 2451

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2024-03-06 08:59 3106

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2024-01-17 12:10 4170

Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a comme...

2024-01-11 11:53 4631

Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2024-01-02 11:58 1922

Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-15 11:14 1884

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-13 16:47 2456

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-12 09:41 2394

Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2023-12-11 13:30 1368

Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-11 13:14 1400

Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-11 12:56 1152

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second annive...

2023-11-24 19:57 2307

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-11-03 09:15 746

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-11-03 09:10 664

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-10-23 19:56 1307